PMID- 37916349
OWN - NLM
STAT- MEDLINE
DCOM- 20231103
LR  - 20231103
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 20
DP  - 2023 Oct
TI  - Efficacy and safety of dupilumab plus topical tacrolimus for atopic dermatitis in 
      6- to 12-year-old patients.
PG  - 9830-9837
LID - 34159 [pii]
LID - 10.26355/eurrev_202310_34159 [doi]
AB  - OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of 
      combining dupilumab with topical tacrolimus for the treatment of atopic 
      dermatitis (AD) in children aged 6 to 12 years. PATIENTS AND METHODS: A total of 
      168 pediatric (aged 6 to 12 years) patients with severe AD admitted to our 
      hospital between April 2022 and April 2023 were included in this retrospective 
      study. These patients are grouped according to different medication methods, 
      assigned them to receive either tacrolimus plus topical corticosteroids (control 
      group) or dupilumab combined with tacrolimus and topical corticosteroids (study 
      group), with 84 patients in each group. Clinical efficacy and adverse reactions 
      were primary clinical endpoints. RESULTS: The use of dupilumab significantly 
      increased the total effective rate for the patients by 14.29%, from 77.38% 
      (65/84) in the control group to 91.67% (77/84) in the study group. Following 
      treatment, patients given dupilumab showed a more significantly decreased 
      peripheral blood eosinophils (EOS) and immunoglobulin E (IgE) levels than those 
      without dupilumab treatment. Patients administered with dupilumab exhibited 
      markedly lower scores on the Patient-oriented Eczema Measure (POEM) at weeks 12 
      and 16 and lower Eczema Area and Severity Index (EASI) scores at weeks 8, 12, and 
      16 when compared to those patients who did not receive dupilumab therapy. At the 
      16-week, 37 patients in the study group obtained a score of 1/0 on the Verified 
      Investigator's Global Assessment (v-IGA) scale, whereas the control group had 24 
      such cases, indicating a significantly higher response rate provided by the 
      protocol incorporating dupilumab. After 16 weeks of treatment, both groups 
      demonstrated a marked decrease in itch numeric rating scale (NRS) scores and 
      Dermatology Life Quality Index (DLQI) scores, with lower scores observed in the 
      study group than in the control group. The absence of a significant difference in 
      the incidence of adverse reactions between the two groups suggested a high safety 
      profile of dupilumab. CONCLUSIONS: The combination of dupilumab with topical 
      tacrolimus demonstrated favorable efficacy in the management of AD in children 
      aged 6 to 12 years. This treatment protocol effectively alleviates symptoms, 
      enhances the quality of life of patients, and shows no increased risk of adverse 
      reactions.
FAU - Gao, S-S
AU  - Gao SS
AD  - Taizhou Central Hospital, Taizhou University Hospital, Taizhou, China. 
      m15957626481@163.com.
FAU - Chen, M
AU  - Chen M
FAU - Wang, R
AU  - Wang R
FAU - Chen, J-G
AU  - Chen JG
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 420K487FSG (dupilumab)
RN  - WM0HAQ4WNM (Tacrolimus)
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Humans
MH  - Child
MH  - *Dermatitis, Atopic/chemically induced
MH  - Tacrolimus/adverse effects
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Double-Blind Method
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Glucocorticoids/therapeutic use
MH  - *Eczema
EDAT- 2023/11/02 06:42
MHDA- 2023/11/03 06:44
CRDT- 2023/11/02 04:43
PHST- 2023/11/03 06:44 [medline]
PHST- 2023/11/02 06:42 [pubmed]
PHST- 2023/11/02 04:43 [entrez]
AID - 34159 [pii]
AID - 10.26355/eurrev_202310_34159 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Oct;27(20):9830-9837. doi: 
      10.26355/eurrev_202310_34159.